News for Biogen Stock (BIIB)

4 Large-Cap Healthcare Stocks You'll Want on Your Radar for the Second Half of 2021

The Motley Fool • 07/18/21

What 18 Analyst Ratings Have To Say About Biogen

Benzinga • 07/16/21

Here's why three hospitals are refusing to treat patients with Biogen's new Alzheimer's drug

Invezz • 07/16/21

Better Biotech Stock: Biogen vs. Annovis Bio

The Motley Fool • 07/16/21

AMD And Biogen Lead The QQQ Lower Thursday

Benzinga • 07/15/21

Biogen falls 8% after 2 major hospital systems refuse to prescribe controversial Alzheimer's drug

Business Insider • 07/15/21

BIIB Stock: The Drug Ban News That Has Biogen Stumbling Today

InvestorPlace • 07/15/21

Biogen Shares Are Trading Lower As Cleveland Clinic, Mount Sinai Decline To Aduhelm Administration

Benzinga • 07/15/21

Biogen's Alzheimer's Drug Aduhelm Review Could Have Been Handled Differently, Says FDA Chief: STAT News

Benzinga • 07/15/21

FDA chief tells reporter 'move on' when pressed on Biogen Alzheimer's drug approval

CNBC • 07/14/21

Biogen (BIIB) In-Licenses Rights to Multiple Sclerosis Drug

Zacks Investment Research • 07/13/21

Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate

Benzinga • 07/13/21

Biogen and Innocare Announce License and Collaboration Agreement For Orelabrutinib, an Innovative CNS Penetrant BTK Inhibitor For the Potential Treatment of Multiple Sclerosis

GlobeNewsWire • 07/12/21

Late-Stage Clinical Study Readouts Biotech Investors Should Watch

The Motley Fool • 07/11/21

Biogen's FDA Approval Takes Center Stage

ETF Trends • 07/09/21

FDA calls for investigation into its contacts with Alzheimer's drug maker

The Guardian • 07/09/21

FDA Requests Probe Into Staff Interactions With Biogen Ahead Of Aduhelm Approval

Benzinga • 07/09/21

FDA calls for federal investigation into approval of Alzheimer's drug

New York Post • 07/09/21

FDA calls for investigation into its own approval of Biogen's Alzheimer's drug

Market Watch • 07/09/21

Biogen stock falls after FDA calls for federal investigation into Alzheimer's drug approval

CNBC • 07/09/21

Biogen stock falls as FDA may investigate Alzheimer's drug approval process

Market Watch • 07/09/21

Biogen (BIIB) Gets FDA Nod for Narrow Label of Aduhelm

Zacks Investment Research • 07/09/21

Should Biogen Worry About a Congressional Investigation Into Its Alzheimer's Disease Drug?

The Motley Fool • 07/09/21

Collaboration Between AbbVie, Biogen and Pfizer Creates World's Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease

GlobeNewsWire • 07/08/21

3 Blue-Chip Stocks to Trade Right Now

InvestorPlace • 07/08/21